Aphria Inc (TSX:APHA) Investors: Pay Attention to These 3 Things

Aphria Inc (TSX:APHA)(NYSE:APHA) has a terrible third quarter. Not only is the company struggling to boost production, but costs are also on the rise. As we head into the fourth quarter, be sure to monitor these three trends.

edit Jars of marijuana

Image source: Getty Images

Aphria Inc (TSX:APHA)(NYSE:APHA) stock is under fire. After reporting third quarter earnings, shares fell by 20%.

Based on nearly any metric, the quarter was horrendous. Aphria struggled to bring new production online, experienced rising corporate and packaging costs, and took a $50 million write-down on its newly acquired Latin America assets.

As we head into the fourth quarter, here are three important trends to monitor.

Production guidance

Demand for cannabis worldwide continues to explode. By 2030, Canadian demand could reach $10 billion annually while the U.S. could surpass $40 billion. To meet this heavy growth, cannabis growers are scrambling to ramp production quickly.

Aphria’s management team has revealed its plans to eventually reach $1 billion in annual sales, but recent quarters have thrown that lofty goal into doubt. In fact, the company now anticipates flat revenue growth for the fourth quarter. What happened?

It turns out that scaling commercial-grade facilities in under 12 months is extraordinarily difficult. We’ve seen other disrupters like Elon Musk attempt similar feats and fail.

If Aphria can’t ramp its production this year, it will be leaving millions of dollars on the table. While new production facilities won’t come online until the second half of 2019, pay close attention to the details when management updates its anticipated production growth.

Cost controls

While scaling production can be difficult, doing it in a cost-efficient manner is even more troublesome.

Last quarter, Aphria’s corporate costs went up across the board. Not only did it need to expand its employee count, but Aphria also failed to automate most of its production as promised.

Incredibly, most of its packaging is still done by hand. If it can’t figure out how to automate this core process, Aphria will struggle to bring down costs alongside its competitors.

In April, company executives specifically highlighted their new focus on “automation and the development of new growing facilities,” but declined to give an exact date by which investors should expect these upgrades, instead noting that they are “mid-term” priorities.

Aphria’s management team keeps pushing its cost-cutting efforts into the future, but if it wants to win back the trust of investors, it needs to provide a solid plan for boosting margins.

Short sellers

Short sellers, investors who bet that a stock will fall in value, can wreak havoc in an instant. While many investors choose to ignore short sellers, pegging them as opportunists, it’s critical that you hear and judge their arguments for yourself.

Earlier this year, Quintessential Capital released a report evaluating Aphria’s stock following months of research, including visits to the company’s facilities in Jamaica, Argentina, and Colombia. The conclusion was dire.

Quintessential Capital charged Aphria insiders with creating and buying shell companies, changing their names and then selling them to Aphria at artificially-inflated prices.

The fact that Aphria has already taken a multi-million dollar write-down on its Latin America acquisition adds considerable credence to these allegations.

If Quintessential Capital is correct, there could be at least $200 million in additional write-offs to come.

You can bet that Quintessential Capital will be looking to push more damning information about Aphria public over the next few months. You’ll want to pay attention to anything else they reveal.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ryan Vanzo has no position in any stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »